Short Interest in China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Drops By 39.9%

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) was the recipient of a large decline in short interest in March. As of March 13th, there was short interest totaling 31,586 shares, a decline of 39.9% from the February 26th total of 52,570 shares. Currently, 3.4% of the shares of the stock are short sold. Based on an average trading volume of 26,742 shares, the short-interest ratio is presently 1.2 days.

China SXT Pharmaceuticals Stock Performance

Shares of NASDAQ:SXTC opened at $1.32 on Friday. The firm has a 50 day moving average of $4.50 and a 200-day moving average of $143.09. China SXT Pharmaceuticals has a 12 month low of $1.28 and a 12 month high of $1,046.99.

China SXT Pharmaceuticals (NASDAQ:SXTC) last announced its quarterly earnings data on Wednesday, December 31st. The company reported ($4.50) earnings per share (EPS) for the quarter. The company had revenue of $0.31 million for the quarter.

Hedge Funds Weigh In On China SXT Pharmaceuticals

A number of institutional investors have recently modified their holdings of SXTC. XTX Topco Ltd bought a new stake in shares of China SXT Pharmaceuticals during the 4th quarter worth $36,000. Virtu Financial LLC grew its position in China SXT Pharmaceuticals by 107.5% in the third quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock valued at $46,000 after acquiring an additional 15,013 shares during the last quarter. Finally, Citadel Advisors LLC bought a new position in China SXT Pharmaceuticals in the third quarter valued at about $78,000. Institutional investors and hedge funds own 5.02% of the company’s stock.

Analyst Ratings Changes

Separately, Wall Street Zen raised China SXT Pharmaceuticals to a “sell” rating in a report on Saturday, February 7th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, China SXT Pharmaceuticals has an average rating of “Sell”.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.